SLPS (Scanning Profiling Profiler) 기반 방법론으로 안구 내 렌즈의 전방 및 후방 산란을 정량적으로 평가

Executive Industry Relevance

Quantitative evaluation of light scattering from intraocular lenses (IOLs) is critical for de-risking optical device portfolios and predicting patient-relevant visual side effects. The scanning light scattering profiler (SLSP) enables non-clinical, full-angle assessment of forward and backward scatter, supporting early identification of designs or materials prone to unwanted optical phenomena. This capability strengthens predictive confidence at the device development inflection point, reducing downstream clinical risk and portfolio attrition.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables hypothesis-driven interrogation of IOL material and design impact on light scatter.
• Supports mechanistic de-risking by quantifying directionality and intensity of scatter.
• Facilitates functional validation of optical targets before clinical translation.

Screening & Assay Development

• Prepares validated optical systems for downstream device screening workflows.
• Standardizes quantitative scatter measurements for reproducibility across IOL candidates.
• Enables scalable, platform-based evaluation of new lens materials and geometries.

Translational & Preclinical Research

• Aligns non-clinical scatter profiles with translational endpoints such as glare and image quality.
• Supports continuity from benchtop evaluation to preclinical device selection.
• Reduces risk of late-stage optical failures by informing design iteration early.

Pipeline & Workflow Integration

The SLSP methodology integrates at the interface of device discovery, lead identification, and preclinical evaluation for ophthalmic implants and optical components.

• Discovery Biology: Quantifies light scatter to clarify mechanistic sources of optical defects.
• Screening: Provides reproducible, quantitative readouts for comparative assessment of IOL candidates.
• Analytics: Delivers angle-resolved scatter data to support statistical comparison of device performance.
• Translational Research: Bridges non-clinical scatter metrics with patient-relevant visual outcomes.
• Enterprise Reuse: Establishes a reusable platform for evaluating diverse optical devices beyond IOLs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in device safety and performance by quantifying scatter directionality and intensity.
• Operational Value: Standardizes measurement protocols for reproducibility and scalability across R&D teams.
• Strategic Value: Enables informed go/no-go decisions and reduces late-stage optical risk in device portfolios.
• Portfolio Impact: Supports risk-adjusted prioritization of IOL and optical device candidates for advancement.

Implementation Considerations

• Requires expertise in optical alignment and photometric instrumentation.
• Demands access to programmable goniophotometer platforms and laser safety infrastructure.
• Necessitates cross-team standardization of scatter measurement parameters and data analysis.
• Adaptable to various optical device formats with appropriate mounting and alignment adjustments.
• Practical limitations include sensitivity to alignment errors and the need for controlled ambient lighting.

Biopharma FAQs